Synthesis of new derivatives of boehmeriasin A and their biological evaluation in liver cancer

Creative Commons License

Guzelcan E. A., Baxendale I. R., Cetin-Atalay R., Baumann M.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.166, pp.243-255, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 166
  • Publication Date: 2019
  • Doi Number: 10.1016/j.ejmech.2019.01.056
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.243-255
  • Keywords: Boehmeriasin A, Natural product analogs, Liver cancer, Cell cycle analysis, HEPATOCELLULAR-CARCINOMA, EPIDEMIOLOGY, CRYPTOPLEURINE, (-)-ANTOFINE, SORAFENIB, ALKALOIDS, ANTOFINE, ANALOGS
  • Middle East Technical University Affiliated: Yes


Two series of boehmeriasin A analogs have been synthesized in short and high yielding processes providing derivatives differing either in the alkaloid's pentacyclic scaffold or its peripheral substitution pattern. These series have enabled, for the first time, comparative studies into key biological properties revealing a new lead compound with exceptionally high activity against liver cancer cell lines in the picomolar range for both well (Huh7, Hep3B and HepG2) and poorly (Mahlavu, FOCUS and SNU475) differentiated cells. The cell death was characterized as apoptosis by cytochrome-C release, PARP protein cleavage and SubG1 cell cycle arrest. Subsequent testing associated apoptosis via oxidative stress with in situ formation of reactive oxygen species (ROS) and altered phospho-protein levels. Compound 19 decreased Akt protein phosphorylation which is crucially involved in liver cancer tumorigenesis. Given its simple synthetic accessibility and intriguing biological properties this new lead compound could address unmet challenges within liver cancer therapy. (C) 2019 Elsevier Masson SAS. All rights reserved.